Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-BH-A0W3-01A-11R-A109-07

— · B

b1cc8dd4-162f-5cf9-b0d8-a4bd49f8908f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
B
subtype
B
overall_survival_months
24

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.380
  • G2M_CHECKPOINT+0.350
  • MITOTIC_SPINDLE+0.320
  • DNA_REPAIR+0.290
  • OXIDATIVE_PHOSPHORYLATION+0.270
  • ESTROGEN_RESPONSE_EARLY+0.190
  • HEME_METABOLISM+0.190
  • INTERFERON_ALPHA_RESPONSE+0.180
  • TGF_BETA_SIGNALING+0.160
  • PI3K_AKT_MTOR_SIGNALING+0.150

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
  • ALLOGRAFT_REJECTION-0.480
  • ANGIOGENESIS-0.440
  • CHOLESTEROL_HOMEOSTASIS-0.400
  • COAGULATION-0.400
  • INFLAMMATORY_RESPONSE-0.370
  • KRAS_SIGNALING_UP-0.370
  • APICAL_JUNCTION-0.330
  • COMPLEMENT-0.330
  • HEDGEHOG_SIGNALING-0.330

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
120050053.LumB
breast-umap@18
—B0.871
2TCGA-E2-A15K-06A-11R-A12P-07
breast-umap@18
—B0.863
320050151.LumB
breast-umap@18
—B0.842
4SJEPD030854_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.837
5MDT-AP-1366
medullo-epn-umap@date-based
MedMedulloblastoma0.809
6MDT-AP-0357
medullo-epn-umap@date-based
MedMedulloblastoma0.806
7MDT-AP-3307
medullo-epn-umap@date-based
MedMedulloblastoma0.805
8TCGA-E2-A15O-01A-11R-A115-07
breast-umap@18
—B0.798
9BS_J8G4SH4Z
medullo-epn-umap@date-based
MedMedulloblastoma0.798
10MNG1070
mng-umap@100
——0.798

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.380Inavolisib— uncovered
G2M_CHECKPOINT0.350Inavolisib— uncovered
MITOTIC_SPINDLE0.320Inavolisib— uncovered
DNA_REPAIR0.290Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.270Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.190Inavolisib— uncovered
HEME_METABOLISM0.190Temsirolimus— uncovered
INTERFERON_ALPHA_RESPONSE0.180Inavolisib— uncovered
TGF_BETA_SIGNALING0.160Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.150Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered
PROTEIN_SECRETION0.080Remibrutinib— uncovered
ADIPOGENESIS0.070Inavolisib— uncovered
MYC_TARGETS_V10.070Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.060Inavolisib— uncovered
UV_RESPONSE_UP0.050Idelalisib— uncovered
FATTY_ACID_METABOLISM0.030Inavolisib— uncovered
NOTCH_SIGNALING0.030Inavolisib— uncovered
PEROXISOME0.020Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.020Inavolisib— uncovered